Mankind Pharma, a fast growing pharmaceutical company, has launched an affordable anti-diabetic product Dynaglipt (teneligliptin) for the diabetic patients of India targeting the middle class and rural diabetic patients of India so as to cater to this growing epidemic.
The company has recently launched this advanced oral anti- diabetic drug as approved by Drug Controller General of India that produces sustained blood glucose control after all three meals and is also safe even in diabetic patients with kidney disease. This molecule comes under the category of DPP-4 inhibitors.
As per International Diabetes Federation (IDF) there were more than 7 crore diabetic patients in India for the year 2014 and this figure will rise significantly to 11 crore. As most of the patient population resides in rural India or belong to middle class, Mankind has launched this affordable anti-diabetic drug so that substantial financial burden of this segment of population in India is reduced. Also many of the patients are unable to offer the cost of anti-diabetes therapy and suffer from serious complications like kidney damage and heart problems.
In past 7 years there have been continuous launch of gliptin which were all costed between Rs.1000 to Rs.1500 for 30 days therapy to a patient. Therefore, launch of Dynaglipt has brought a hope for anti-diabetic therapy to patients in India. Dynaglipt, is the latest new generation oral anti-diabetic drug manufactured by Mankind which has received regulatory approval and is priced competitively at nearly Rs.600 only for 30 days therapy to a patient. Furthermore, this gliptin tablet is required to be taken or consumed just once in a day as compared to other diabetic drugs which are required to be taken after every meals. One dose itself, provides blood glucose control after all three meals.
R.C Juneja, chairman and founder, Mankind Pharma said that currently there are 1.9 million of the 62 million diabetic patients in India who are estimated to be on gliptin therapy. Dynaglipt as an anti-diabetic drug by Mankind Pharma is most affordable gliptin with unique advantages and availability all across India and will definitely bring delight for millions of diabetic patients in India. Also, this molecule could help bring down the cost of medicines by approx. 50 per cent.
Along with affordable pricing of Dynaglipt, it is also safe in patients with kidney disorders and have multiple benefits in patients with heart diseases. Mankind aims to achieve revenue of Rs.4,200 crore this year, with the launch of Dynaglipt the diabetes segment of Mankind Pharma will contribute Rs.200 crore to the revenue. Currently Mankind is positioned as no. 14th in same.